Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Prospective, Open Label, Multicenter, Two-Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Immunoglobulin G4-Related Disease

NCT07061938 is registered in ClinicalTrials.gov with Acepodia Biotech, Inc. as lead sponsor.

NCT NCT07061938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07061938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Prospective, Open Label, Multicenter, Two-Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Immunoglobulin G4-Related Disease
Lead sponsor
Acepodia Biotech, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2026
Completion date
September 20, 2029
Enrollment
34 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

igg4 related disease